NASDAQ · RYTM
Healthcare · Biotechnology
$92.57
Down-$0.50 (-0.54%)
Updated Oct 31, 2026, 2:09 PM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · RYTM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
RYTM closed at $92.57 after 21 trading sessions, down 0.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $93.48 | $95.595 | $91.42 | $92.57 | 431.66K |
| Oct 29, 2026 | $93.00 | $94.16 | $92.515 | $93.07 | 760.47K |
| Oct 28, 2026 | $91.37 | $92.70 | $91.05 | $91.97 | 533.87K |
| Oct 27, 2026 | $89.36 | $92.72 | $88.72 | $92.18 | 400.17K |
| Oct 26, 2026 | $90.07 | $90.81 | $89.00 | $89.47 | 289.45K |
| Oct 23, 2026 | $90.44 | $90.44 | $88.56 | $89.27 | 536.88K |
| Oct 22, 2026 | $88.85 | $90.95 | $87.59 | $90.90 | 516.39K |
| Oct 21, 2026 | $91.02 | $92.18 | $88.12 | $88.62 | 511.34K |
| Oct 20, 2026 | $88.56 | $91.88 | $88.56 | $90.20 | 877K |
| Oct 19, 2026 | $87.04 | $88.76 | $86.59 | $88.23 | 378.79K |
| Oct 16, 2026 | $88.20 | $88.62 | $85.91 | $86.17 | 367.04K |
| Oct 15, 2026 | $88.41 | $90.42 | $87.61 | $87.97 | 644.56K |
| Oct 14, 2026 | $86.41 | $88.14 | $85.38 | $86.71 | 585.84K |
| Oct 13, 2026 | $89.63 | $90.505 | $86.35 | $86.61 | 623.19K |
| Oct 12, 2026 | $91.05 | $91.4175 | $89.49 | $89.82 | 543.82K |
| Oct 9, 2026 | $89.67 | $93.35 | $89.41 | $90.78 | 1.41M |
| Oct 8, 2026 | $89.05 | $90.94 | $87.01 | $89.64 | 1.01M |
| Oct 7, 2026 | $90.77 | $91.37 | $88.23 | $88.45 | 939.42K |
| Oct 6, 2026 | $92.55 | $94.47 | $90.07 | $90.77 | 992.87K |
| Oct 5, 2026 | $93.95 | $94.408 | $89.53 | $92.45 | 1.03M |
| Oct 2, 2026 | $94.97 | $95.315 | $92.66 | $92.83 | 503.54K |
The latest Smart Investors Daily articles mentioning RYTM.
Company
Market Activity
Research & News
RYTM research
Company profile and research snapshot.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 16, 2026 | William Blair | Outperform | — |
| Oct 15, 2026 | JP Morgan | Overweight | — |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Aug 28, 2026 | Deutsche Bank | Hold | — |
No generated briefing is available yet.
Benzinga · Oct 21, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.37% on an annualized basis producing an average annual return of 51.51%. Currently, Rhythm Pharmaceuticals has a market
Yahoo · Oct 21, 2026
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update. Also today, Rhythm announced participation in two upcoming investor conferen
Benzinga · Oct 16, 2026
William Blair analyst Alethia Young initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform rating.
Benzinga · Oct 15, 2026
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $146 to $145.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RYTM.
